Ya-Chien Yang

Prof. Ya-Chien Yang

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 1996 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
FKF N Ko
F N Ko
YYYa-Chien Yang
Ya-Chien Yang
SHS C Huang
S C Huang
JOJ T Ou
J T Ou
The mitogenic effect of activated coagulation factor X (factor Xa) was examined in cultured aortic smooth muscle cells (VSMC) from Wistar-Kyoto rats (WKY). Factor Xa stimulated DNA synthesis and cell growth in VSMC, not through the phospholipase C-protein kinase C pathway because increase of inositol monophosphate (IP) accumulation and intracellular Ca2+ concentration was not observed, but probably via the PDGF receptor tyrosine kinase pathway since the pathway's components, Ras, Raf-1, MAPK (both 42 and 44 kD), and the transcription factors, c-Fos and c-Jun, were activated. These appeared to be effected by the serine protease activity of factor Xa, since in the presence of serine protease inhibitors such as PMSF, leupeptin, benzamidine, TAP anticoagulant, and TLCK, the latter three being specific inhibitors of the factor Xa, active site, the effects were completely blocked. Anti-factor Xa mAb, 5224, which specifically negated the activity of factor Xa, also inhibited completely the mitogenic effect of factor Xa, but not that of thrombin. Addition of PDGF did not affect the effect of factor Xa, which, however, was inhibited by anti-PDGF-AB antibody. This observation and the activation of PDGF receptor tyrosine kinase pathway suggested that the factor Xa might exert its effect via PDGF-like function. Direct measurement confirmed that factor Xa stimulated the release of PDGF from VSMC. Factor Xa, therefore, exerts serine protease activity on VSMC, causing somehow the release of PDGF, that in turn acts on the PDGF receptor tyrosine kinase; the pathway is then turned on, leading eventually to DNA synthesis and cell proliferation.

1 January 2003 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
JLJen-Kou Lin
Jen-Kou Lin
SCShih-Ching Chang
Shih-Ching Chang
YYYa-Chien Yang
Ya-Chien Yang
ALAnna Fen-Yau Li
Anna Fen-Yau Li

1 November 2018 in Hepatology
Verified
Journal Article
Closed access
PDF file
YWYa‐Hui Wang
Ya‐Hui Wang
YCYa-Hui Chuang
Ya-Hui Chuang
CWChih‐Feng Wu
Chih‐Feng Wu
MJMeng‐Chin Jan
Meng‐Chin Jan
WWWan‐Jung Wu
Wan‐Jung Wu
MYMing-Whei Yu
Ming-Whei Yu

1 January 2013 in Evidence-Based Complementary and Alternative Medicine
Verified
Journal Article
Open access
PDF file
CCChun-Chieh Chen
Chun-Chieh Chen
MSMunisamy Sureshbabul
Munisamy Sureshbabul
HCHuei-Wen Chen
Huei-Wen Chen
YLYu-Shuang Lin
Yu-Shuang Lin
JLJen-Yi Lee
Jen-Yi Lee
SYSung-Liang Yu
Sung-Liang Yu
Colorectal cancer (CRC) is a serious public health problem that results due to changes of diet and various environmental stress factors in the world. Curcumin is a traditional medicine used for treatment of a wide variety of tumors. However, antimetastasis mechanism of curcumin on CRC has not yet been completely investigated. Here, we explored the underlying molecular mechanisms of curcumin on metastasis of CRC cellsin vitroandin vivo. Curcumin significantly inhibits cell migration, invasion, and colony formationin vitroand reduces tumor growth and liver metastasisin vivo. We found that curcumin suppresses Sp-1 transcriptional activity and Sp-1 regulated genes including ADEM10, calmodulin, EPHB2, HDAC4, and SEPP1 in CRC cells. Curcumin inhibits focal adhesion kinase (FAK) phosphorylation and enhances the expressions of several extracellular matrix components which play a critical role in invasion and metastasis. Curcumin reduces CD24 expression in a dose-dependent manner in CRC cells. Moreover, E-cadherin expression is upregulated by curcumin and serves as an inhibitor of EMT. These results suggest that curcumin executes its antimetastasis function through downregulation of Sp-1, FAK, and CD24 and by promoting E-cadherin expression in CRC cells.

1 August 2014 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CCChun-Chieh Chen
Chun-Chieh Chen
HCHsuan-Yu Chen
Hsuan-Yu Chen
KSKang-Yi Su
Kang-Yi Su
QHQi-Sheng Hong
Qi-Sheng Hong
BYBo-Shiun Yan
Bo-Shiun Yan
SYSung-Liang Yu
Sung-Liang Yu
Rationale: Despite advances in treatment and prognosis of non–small cell lung cancer (NSCLC), patient outcomes are still unsatisfactory. Objectives: To reduce the morbidity and mortality of patients with NSCLC, a more comprehensive understanding of mechanisms involved in cancer progression is urgently needed. Methods: By comparison of gene expression profiles in the cell line pair with differential invasion ability, CL1–0 and CL1–5, we found that Shisa3 was highly expressed in the low invasive cells. The effect of Shisa3 on invasion, migration, proliferation, apoptosis, epithelial-mesenchymal transition, and anchorage-independent growth activities in vitro and on tumor growth and metastasis in mice models were examined. The underlying mechanism of Shisa3 was explored by microarray and pathway analysis. Finally, the correlation of Shisa3 expression and clinical outcome was also calculated. Measurements and Main Results: We identified Shisa3 as a novel tumor suppressor, which induces β-catenin degradation resulting in suppression of tumorigenesis and invasion in vitro. Shisa3 decreased the tumor growth in mice with subcutaneous implantation and reduced the number of metastatic nodules in mice with tail vein injection and orthotopic implantation. Shisa3 performs the tumor suppression activity through WNT signaling predicted by microarray analysis. Our data found that Shisa3 accelerates β-catenin degradation and was positively associated with overall survival and progression-free survival of NSCLC. Conclusions: Our results reveal that Shisa3 acts as a tumor suppressor by acceleration of β-catenin degradation and provide new insight for cancer prognosis and therapy.

17 April 2014 in International Journal of Cancer
Verified
Journal Article
Open access
PDF file
TJTzu‐Ming Jao
Tzu‐Ming Jao
MTMing‐Hong Tsai
Ming‐Hong Tsai
HLHoi‐Yan Lio
Hoi‐Yan Lio
WWWei‐Ting Weng
Wei‐Ting Weng
CCChun‐Chieh Chen
Chun‐Chieh Chen
YYYa-Chien Yang
Ya-Chien Yang
Protocadherin 10 (PCDH10), a novel tumor suppressor gene in human cancers, is located in a common deleted region at chromosome 4q28 in colorectal cancer (CRC). This study aimed to ascertain the genetic loss of PCDH10 and its clinical relevance in CRC and to explore the tumor suppressor function of PCDH10. The genetic deletion of PCDH10 was determined in 171 pairs of primary tumors and corresponding normal mucosae by loss of heterozygosity study. In total, 53 carcinomas were positive for allelic loss of PCDH10. The genetic aberration was significantly associated with tumor progression and distant metastasis (p = 0.021 and p = 0.018, respectively) and was an independent predictor of poor survival for CRC patients (p = 0.005). Expression of PCDH10 gene was silenced or markedly down‐regulated in all of 12 CRC cell lines tested and in 41 of 53 colorectal carcinomas compared with their matched normal mucosae. Ectopic expression of PCDH10 suppressed cancer cell proliferation, anchorage‐independent growth, migration and invasion in vitro. Subcutaneous injection of PCDH10‐expressing CRC cells into SCID mice revealed the reduction of tumor growth compared with that observed in mock‐inoculated mice. Furthermore, through intrasplenic implantation, the re‐expression of PCDH10 in silenced cells restrained liver metastasis and improved survival in SCID mice. In conclusion, PCDH10 is a pivotal tumor suppressor in CRC, and the loss of its function promotes not only tumor progression but also liver metastasis. In addition, the genetic deletion of PCDH10 represents an adverse prognostic marker for the survival of patients with CRC.